Herceptin Less-Frequent Dosing Is Preferred For Early-Stage Breast Cancer, NICE Says
This article was originally published in The Pink Sheet Daily
U.K.’s NICE supports adoption of three-week interval dosing for trastuzumab for early-stage HER2-positive breast cancer.
You may also be interested in...
Not inspired by its clinical effectiveness, NICE has said it will not recommend Roche's “over-priced” Kadcyla for breast cancer.
A supplemental BLA for an early adjuvant breast cancer indication for Herceptin will have a mid-August user fee date, if granted priority review
Roche will consider requesting a re-examination of the negative decision by the Committee for Medicinal Products for Human Use.